Skip to content
logo MSD Oncology Clinical Trials
  • Homepage
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Gastric
    • Gynaecologic
    • Haematological
    • Head and Neck
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Oesophageal
    • Paediatric
    • Prostate
    • Solid Tumours
  • About
  • Common Questions
  • For HCPs
  • English (AU)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Condition: Carcinoma, Hepatocellular

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

Condition: Carcinoma, Hepatocellular

Safety and Efficacy of Lenvatinib With Pembrolizumab in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

March 7, 2022

By Tyler Kalist

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility
  • Contact Us

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Merck Sharp & Dohme (Australia) Pty Limited. Level 1 - Building A, 26 Talavera Road, Macquarie Park, NSW 2113
AU-NON-00575 – December 2022

Accessibility

Accessibility